The Liver Meeting (AASLD 2012)

November 9-13, 2012, Boston

Coverage of the 2014 AASLD Liver Meeting

HIVandHepatitis.com coverage of the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2014) in Boston, November 7-11, 2014.

Conference highlights include new interferon-free therapy for hepatitis C -- including options for people with cirrhosis, and liver transplant recipients -- treatment for hepatitis B, and prevention and management of advanced liver disease.

Full listing by topic

The Liver Meeting website

12/2/14

alt

Coverage of the 2013 AASLD Liver Meeting

HIVandHepatitis.com coverage of the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2013) in Washington, DC, November 1-5, 2013.

Conference highlights include treatment for hepatitis B and C, new direct-acting HCV drugs, interferon-free hepatitis C therapy, management of liver disease complications, HIV/HBV and HIV/HCV coinfection, and prevention and treatment of hepatocellular carcioma.

Full listing by topic

10/30/13

alt

AASLD 2012: Entecavir Shows Good Efficacy for Black and Hispanic Hepatitis B Patients

The nucleoside analog entecavir (Baraclude) worked as well for previously untreated African-American and Hispanic/Latino hepatitis B patients as it did for the majority white and Asian study populations in prior clinical trials, according to a poster presented at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) last month in Boston.

alt

Read more:

AASLD 2012: Interferon Lambda Shows Good HCV Suppression, Better Tolerated than Interferon Alfa

Pegylated interferon lambda works as well as pegylated interferon alfa for treating chronic hepatitis C, but with fewer side effects, according to studies presented at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) last month in Boston. Researchers also reported the first data on interferon lambda in combination with direct-acting antivirals.alt

Read more:

AASLD 2012: Adding Pegylated Interferon to Entecavir Improves HBV Treatment Response

Intensifying entecavir (Baraclude) treatment for hepatitis B by adding pegylated interferon lowers HBV viral load and increases the likelihood of hepatitis B "e" antigen (HBeAg) loss, according to a report at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) last month in Boston. A related study found that hepatitis B surface antigen (HBsAg) levels during treatment can be used to predict response to interferon. alt

Read more: